Journal: Pharmaceutics
Article Title: Retinal Protection of New Nutraceutical Formulation
doi: 10.3390/pharmaceutics17010073
Figure Lengend Snippet: Immunostaining of RNA-binding protein and mRNA Processing Factor-positive (RBPMS+) cells for the analysis of retinal ganglion cell (RGC) density in flat-mount retinas. ( a ) RBPMS+ RGCs in central ( A , B ) and peripheral areas ( C , D ) of control (CTRL) and Epicolin formulation-treated mice. Quantification was carried out on the whole retina ( b ) and on both central and peripheral areas of the retina ( c ). Scale bar corresponds to 50 μm. The data were plotted as means ± SEMs (n = 12 retinas per group). * p ≤ 0.05 vs. CTRL; ° p ≤ 0.05 vs. CTRL c; † p ≤ 0.05 vs. CTRL p. Unpaired t -test. CTRL central (CTRL c), CTRL periphery (CTRL p), Epicolin central (Epicolin c), and Epicolin periphery (Epicolin p).
Article Snippet: Primary antibody for RNA binding protein, mRNA Processing Factor (RBPMS, RNA-binding protein with multiple splicing), was purchased from Novus Biologicals, part of Bio-Techne SRL (Milan, Italy).
Techniques: Immunostaining, RNA Binding Assay, Control, Formulation